A high expression of ERCC5 mRNA revealed a favorable OS for patients with diffuse-type GC (HR=0.56, 95% CI=0.31–1, P=0.048, Figure 8(c)), but ERCC5 had no impact on OS and the Lauren classification of GC patients (Figures 8(a), 8(b), and 8(d)). Here, ERCC5 is linked to gastric cancer.